Idiopathic Pulmonary Fibrosis (IPF) drug development is still hindered by numerous challenges. In order to bring the 2nd and 3rd generation of IPF therapeutics to market, it’s vital that these hurdles are overcome.
The IPF Summit has been built from extensive market research with industry experts at Boehringer Ingelheim, GSK, BMS, Fibrogen, Promedior and a host of other leading biopharma and academic institutions.
Across 3 intensive days and more than 20 sessions, this industry-led forum will cover IPF drug development from late discovery to early clinical studies.
You’ll benefit from a really niche focus, enabling you to join, engage and learn from experts across the IPF field. Leave bursting with actionable insights, ideas and solutions to propel your IPF pipeline forward.
Confirmed topics include the validation of novel targets to better recapitulate IPF, robust in vitro & in vivo systems, and identifying robust biomarkers to enhance preclinical research and better stratify patient populations.
Join over 40 renowned organizations who have already confirmed their attendance and will be taking advantage of this opportunity.
AdAlta – Aragen Bioscience – AstraZeneca – Bellerophon Therapeutics – Biogen – Boehringer Ingelheim – Bristol-Myers Squibb – Cedars-Sinai Medical Center – Celgene Corporation – Dartmouth – FibroGen – Genentech – Genoa Pharmaceuticals – Ironwood Pharmaceuticals – Kadmon Corporation- Lung Therapeutics – Mayo Clinic – MedImmune – Melior Discovery NuMedii – Pliant Therapeutics- Promedior – Pulmonary Fibrosis Foundation – RespirPharm Solutions – Segue Therapeutics- Synairgen Research – University of California Los Angeles – University of Texas – Vertex Pharmaceuticals – Weill Cornell Medical College